Chapuis

Affini-T Therapeutics is a clinical-stage biotechnology company focused on developing potentially curative T-cell receptor (TCR) engineered T-cell therapies for patients with solid tumors driven by oncogenic mutations. Co-founded by Dr. Aude Chapuis and other experts from the Fred Hutchinson Cancer Center, the company leverages a proprietary platform to identify and engineer high-affinity TCRs that target core genetic drivers of cancer, such as KRAS and TP53. Their approach combines advanced synthetic biology with T-cell engineering to overcome the immunosuppressive tumor microenvironment and provide durable clinical outcomes. Affini-T's pipeline includes programs targeting prevalent mutations in lung, colorectal, and pancreatic cancers, as well as hematologic malignancies.